Delisting riskPopularity #4,526
Evogene (EVGN)
AI-guided small-molecule discovery for medicines and crop protection.
$0.4935
After hours+0.02 (+3.31%)
At close$0.4777(+3.17%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Insiders | 0.01% | 1.1K ADS | |
|---|---|---|---|
| 1 holder · as of Aug 26, 2026 | |||
| Other | 99.99% | 8.72M ADS | |
| remainder | |||
8.72M ADS as of Sep 22, 2026 · holders as of their latest filing
13F
No 13F holders on record.
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| L.I.A. Pure Capital Ltd.incl. Kfir Silberman, Ron Yair Peled +1 more | 19.35% | 3.06M | 13D | Sep 11, 2026 |
| Armistice Capital, LLC | 9.99% | 1.10M | 13G | May 15, 2026 |
| Recanati Leon | 8.60% | 1.35M | 13D | Sep 11, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 4, 2026 | Gabi Tarcicofficer: Chief Development Officer | Purchase | 1,129 | $0.6000 | 1,129 |
| Aug 11, 2026 | Leon Recanatidirector | Purchase | 460,000 | $0.6350 | 1,343,886 |
| Aug 4, 2026 | Leon Recanatidirector | Purchase | 800,000 | $0.5000 | 883,886 |
House and Senate disclosures
Not reported.